Novo Nordisk clinical trial pipeline

15 trials changed in the last 30 days: 0 stopped, 11 with notable changes, 4 with minor changes only.

1. Notable

   Adverse Event Data Collection From the EUHASS Registry on…Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol

   Primary and study completion pushed from Feb 1, 2026 to Dec 1, 2026

   Novo Nordisk A/S·Not specified· NCT04682145· Registry history of NCT04682145 on ClinicalTrials.gov (opens the registry)

   Oct 8, 2026

2. Notable

   Research Study to Look at Long-term Treatment With a Medicine…Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 · Heart Failure Due to Transthyretin Amyloidosis

   Primary endpoint(s) modified

   Also in this update: Trial sites expanded: 35 → 38 locations; Study completion pushed from Aug 15, 2028 to Feb 9, 2030; and 1 more change in the last 30 days

   Novo Nordisk A/S·Phase 2· NCT06260709· Registry history of NCT06260709 on ClinicalTrials.gov (opens the registry)

   Sep 30, 2026

3. Notable

   SCALA-TK-CM · Real-World Cohort Study

   Primary endpoint(s) modified

   Also in this update: Trial status changed: Not Yet Recruiting → Active, Not Recruiting

   Novo Nordisk A/S·Not specified· NCT07781371· Registry history of NCT07781371 on ClinicalTrials.gov (opens the registry)

   Sep 30, 2026

4. Notable

   Research Study Investigating How · Overweight or Obesity, With or…Research Study Investigating How · Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication

   Recruitment opened

   Also in this update: Start date changed from estimate of Sep 30, 2026 to Oct 5, 2026

   Novo Nordisk A/S·Phase 1· NCT07855133· Registry history of NCT07855133 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

5. Notable

   Research Study Investigating How · Overweight or Obesity, With or…Research Study Investigating How · Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication

   Recruitment opened

   Novo Nordisk A/S·Phase 1· NCT07868354· Registry history of NCT07868354 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

6. Notable

   Research Study on How · Type 2 Diabetes Tolerate Switching From…Research Study on How · Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

   Recruitment opened

   Novo Nordisk A/S·Phase 3· NCT07817251· Registry history of NCT07817251 on ClinicalTrials.gov (opens the registry)

   Sep 30, 2026

7. Notable

   AMAZE 9 · Zenagamtide Tablets Help · Excess Body Weight Lose…AMAZE 9 · Zenagamtide Tablets Help · Excess Body Weight Lose Weight

   Recruitment opened

   Also in this update: Trial sites expanded: 37 → 41 locations

   Novo Nordisk A/S·Phase 3· NCT07720271· Registry history of NCT07720271 on ClinicalTrials.gov (opens the registry)

   Sep 28, 2026

8. Notable

   AMAZE 7 · Zenagamtide Helps · Excess Body Weight Lose Weight…AMAZE 7 · Zenagamtide Helps · Excess Body Weight Lose Weight Compared to Semaglutide

   Recruitment opened

   Novo Nordisk A/S·Phase 3· NCT07668414· Registry history of NCT07668414 on ClinicalTrials.gov (opens the registry)

   Sep 28, 2026

9. Notable

   Research Study Looking at the Effect of Timing of Meal After…Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body · Overweight or Obesity

   Recruitment opened

   Novo Nordisk A/S·Phase 1· NCT07815067· Registry history of NCT07815067 on ClinicalTrials.gov (opens the registry)

   Oct 2, 2026

10. Notable

    See How Safe a New Medicine (NNC0705-0002) is in Healthy People

    Recruitment opened

    Novo Nordisk A/S·Phase 1· NCT07797855· Registry history of NCT07797855 on ClinicalTrials.gov (opens the registry)

    Sep 30, 2026

11. Notable

    Patient Preferences · Haemophilia A With and Without Inhibitors: a…Patient Preferences · Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany

    Enrolling by invitation only

    Also in this update: Primary and study completion pushed from Oct 26, 2026 to Dec 26, 2026

    Novo Nordisk A/S·Not specified· NCT07653139· Registry history of NCT07653139 on ClinicalTrials.gov (opens the registry)

    Oct 6, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.